Radioembolization for hepatocellular carcinoma: A review of the evidence and treatment recommendations

Bruno Sangro, Riad Salem, Andrew Kennedy*, Douglas Coldwell, Harpreet Wasan

*Corresponding author for this work

Research output: Contribution to journalReview article

68 Citations (Scopus)

Abstract

Treatment decisions for hepatocellular carcinoma involve the evaluation of multiple factors including tumor size, location, and morphology; comorbidity and/or extrahepatic disease; health status; patient preferences; and the treating physician's expertise and skill. For patients who are not candidates for transplant or resection, and for whom other therapies (radiofrequency ablation, systemic chemotherapies, transarterial embolization or chemoembolization), may have limited efficacy, an urgent need for bridging procedures, to enable surgery or ablation, or meet transplantation criteria, has led to investigations with radioembolization. A number of recent reports have supported the effectiveness of Yttrium-90 (90Y) labeled microspheres to treat intermediate and advanced disease in patients with good overall functional status and liver reserve; patients with portal vein involvement and in a limited role to treat unresectable early-stage disease. This review addresses response rates and survival benefit following radioembolization in different patient populations, in centers throughout Europe, North America, and Asia, and across the spectrum of patients presenting with various prognostic factors. By using stringent selection criteria and conservative models for calculating radiation dosage, radioembolization can be performed safely even in cirrhotic patients, without postembolization syndrome or radiation-induced liver disease, and even with multiple treatments to whole or part of the liver.

Original languageEnglish (US)
Pages (from-to)422-431
Number of pages10
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume34
Issue number4
DOIs
StatePublished - Aug 1 2011

Fingerprint

Hepatocellular Carcinoma
Therapeutics
Northern Asia
Yttrium
Radiation Dosage
Radiation Injuries
Patient Preference
Liver
North America
Portal Vein
Microspheres
Patient Selection
Health Status
Comorbidity
Liver Diseases
Survival Rate
Transplantation
Physicians
Transplants
Drug Therapy

Keywords

  • hepatic
  • hepatocellular
  • liver
  • tumor
  • yttrium-90

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{b6c015d7b91a4a0596e560fee9a4aee2,
title = "Radioembolization for hepatocellular carcinoma: A review of the evidence and treatment recommendations",
abstract = "Treatment decisions for hepatocellular carcinoma involve the evaluation of multiple factors including tumor size, location, and morphology; comorbidity and/or extrahepatic disease; health status; patient preferences; and the treating physician's expertise and skill. For patients who are not candidates for transplant or resection, and for whom other therapies (radiofrequency ablation, systemic chemotherapies, transarterial embolization or chemoembolization), may have limited efficacy, an urgent need for bridging procedures, to enable surgery or ablation, or meet transplantation criteria, has led to investigations with radioembolization. A number of recent reports have supported the effectiveness of Yttrium-90 (90Y) labeled microspheres to treat intermediate and advanced disease in patients with good overall functional status and liver reserve; patients with portal vein involvement and in a limited role to treat unresectable early-stage disease. This review addresses response rates and survival benefit following radioembolization in different patient populations, in centers throughout Europe, North America, and Asia, and across the spectrum of patients presenting with various prognostic factors. By using stringent selection criteria and conservative models for calculating radiation dosage, radioembolization can be performed safely even in cirrhotic patients, without postembolization syndrome or radiation-induced liver disease, and even with multiple treatments to whole or part of the liver.",
keywords = "hepatic, hepatocellular, liver, tumor, yttrium-90",
author = "Bruno Sangro and Riad Salem and Andrew Kennedy and Douglas Coldwell and Harpreet Wasan",
year = "2011",
month = "8",
day = "1",
doi = "10.1097/COC.0b013e3181df0a50",
language = "English (US)",
volume = "34",
pages = "422--431",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Radioembolization for hepatocellular carcinoma : A review of the evidence and treatment recommendations. / Sangro, Bruno; Salem, Riad; Kennedy, Andrew; Coldwell, Douglas; Wasan, Harpreet.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 34, No. 4, 01.08.2011, p. 422-431.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Radioembolization for hepatocellular carcinoma

T2 - A review of the evidence and treatment recommendations

AU - Sangro, Bruno

AU - Salem, Riad

AU - Kennedy, Andrew

AU - Coldwell, Douglas

AU - Wasan, Harpreet

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Treatment decisions for hepatocellular carcinoma involve the evaluation of multiple factors including tumor size, location, and morphology; comorbidity and/or extrahepatic disease; health status; patient preferences; and the treating physician's expertise and skill. For patients who are not candidates for transplant or resection, and for whom other therapies (radiofrequency ablation, systemic chemotherapies, transarterial embolization or chemoembolization), may have limited efficacy, an urgent need for bridging procedures, to enable surgery or ablation, or meet transplantation criteria, has led to investigations with radioembolization. A number of recent reports have supported the effectiveness of Yttrium-90 (90Y) labeled microspheres to treat intermediate and advanced disease in patients with good overall functional status and liver reserve; patients with portal vein involvement and in a limited role to treat unresectable early-stage disease. This review addresses response rates and survival benefit following radioembolization in different patient populations, in centers throughout Europe, North America, and Asia, and across the spectrum of patients presenting with various prognostic factors. By using stringent selection criteria and conservative models for calculating radiation dosage, radioembolization can be performed safely even in cirrhotic patients, without postembolization syndrome or radiation-induced liver disease, and even with multiple treatments to whole or part of the liver.

AB - Treatment decisions for hepatocellular carcinoma involve the evaluation of multiple factors including tumor size, location, and morphology; comorbidity and/or extrahepatic disease; health status; patient preferences; and the treating physician's expertise and skill. For patients who are not candidates for transplant or resection, and for whom other therapies (radiofrequency ablation, systemic chemotherapies, transarterial embolization or chemoembolization), may have limited efficacy, an urgent need for bridging procedures, to enable surgery or ablation, or meet transplantation criteria, has led to investigations with radioembolization. A number of recent reports have supported the effectiveness of Yttrium-90 (90Y) labeled microspheres to treat intermediate and advanced disease in patients with good overall functional status and liver reserve; patients with portal vein involvement and in a limited role to treat unresectable early-stage disease. This review addresses response rates and survival benefit following radioembolization in different patient populations, in centers throughout Europe, North America, and Asia, and across the spectrum of patients presenting with various prognostic factors. By using stringent selection criteria and conservative models for calculating radiation dosage, radioembolization can be performed safely even in cirrhotic patients, without postembolization syndrome or radiation-induced liver disease, and even with multiple treatments to whole or part of the liver.

KW - hepatic

KW - hepatocellular

KW - liver

KW - tumor

KW - yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=79961169205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961169205&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181df0a50

DO - 10.1097/COC.0b013e3181df0a50

M3 - Review article

C2 - 20622645

AN - SCOPUS:79961169205

VL - 34

SP - 422

EP - 431

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -